TCANCER
LIVE

Serial Number

79437944

Owner

HS Diagnomics GmbH

Attorney

Nicholas D. Wells

Filing Date

Apr 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TCANCER Trademark

Serial Number: 79437944

TCANCER is a trademark filed by HS Diagnomics GmbH on April 24, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

HS Diagnomics GmbH

Schloßstr. 110

Entity Type: 98

Trademark Details

Filing Date

April 24, 2025

Registration Date

Not Registered

Published for Opposition

May 5, 2026

Goods & Services

Chemical products in the nature of chemical reagents for medical diagnosis; diagnostic preparations for medical use through using t-cell receptors (tcrs); diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations; diagnostic reagents for medical and veterinary use in in vitro diagnosis; diagnostic substances for medical use; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, individual medical diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, tumour identification; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection in oncology; diagnostic test reagents comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for veterinary use; indicators for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; medical diagnostic reagents; medical preparations for the treatment of cancer; pharmaceutical drugs in the nature of preparations for the treatment and prevention of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment and prevention of cancer; pharmaceutical preparations for diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for diagnostic purposes, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for individual medical diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for medical purposes for the treatment and prevention of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in cancer diagnosis; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for individual medical diagnosis in the nature of disease detection of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in oncology for testing of bodily fluids for use in cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; pharmaceutical preparations for suppressing tumours; pharmaceutical preparations, namely, protein arrays for medical diagnosis purposes for the diagnosis of diseases; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating cancer; pharmaceutical products, medical and veterinary preparations, namely, diagnostic preparations for medical or veterinary purposes; pharmaceuticals products for the treatment of cancer; pharmaceutical products for treating cancer; preparations for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; reactants for medical diagnosis, namely, diagnostic preparations for medical use in in vivo diagnosis; reagents and preparations for use in the nature of diagnostic test reagents for medical purposes; reagents for diagnostic tests for medical use; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for profiling, in particular genomic and proteomic profiling, for use in the selection of therapeutics for cancer patients; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for the diagnosis of diseases in the nature of cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptors (tcrs) for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptors (tcrs) for oncological purposes for treating cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptor (tcr) clusters for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptor (tcr) clusters for oncological purposes for treating cancer; tumour suppressing agents; immunomodulators, namely, pharmaceutical preparations for treatment of cancer; immunostimulants; immunotherapeutic agents, namely, pharmaceutical preparations for treatment of cancer; pharmaceutical products in the nature of preparations for the treatment of autoimmune diseases and autoimmune disorders, pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of immune system related disorders

Maintenance of data in computer databases featuring medical patient information; maintenance of data in computer databases featuring oncological information; maintenance of data in medical computer databases; maintenance of data in computer databases

Healthcare services, namely, computerised medical evaluation and diagnostic services in the fields of immunology, oncology, infectiology and vaccines; healthcare services, namely, computerised medical diagnostic services in the fields of immunology, oncology, infectiology and vaccines

Blood analysis services for scientific purposes; development of database services featuring medical patient information; development of database services featuring oncological information; development of database services featuring sequenced t-cell receptors (tcrs); development of medical database services; development of database services; development of pharmaceutical preparations and medicines; research laboratory services in the medical field; maintenance of online databases for others; medical research in the field of immunology, oncology, infectiology and vaccines; medical research services, namely, performing analyses for medical research; performing chemical analyses; platform as a service (PAAS) featuring computer software platforms for use in database management and t-cell receptor (tcr) identification and characterisation; research and development of pharmaceutical preparations for treating malignant tumours; research of pharmaceuticals; research services in the field of medical analyses and diagnostics; scientific research and development in identification of tumour antigens; scientific research and development in the field of immunology, oncology, infectiology and vaccines; scientific research and development in the field of t-cell receptors (tcrs); scientific research and development; software as a service (SAAS) featuring software for database management and use in t-cell receptor (tcr) identification and characterisation; scientific research and development services for medical and pharmaceutical purposes in the fields of immunology, oncology, infectiology and vaccines; research and development services in connection with pharmaceutical and medical preparations, medicine and pharmaceuticals in the fields of immunology, oncology, infectiology and vaccines; computerised medical evaluation and diagnostic services in the nature of medical research services in the fields of immunology, oncology, infectiology and vaccines

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 5, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 5, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Apr 30, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 29, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 15, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 15, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 3, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 1, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2026 TROA
REFUSAL PROCESSED BY IB
Feb 5, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 18, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 18, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 11, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 10, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 3, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 2, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 2, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 27, 2025 REPR